|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-2.61/-1.01
|
企业价值
4.56M
|
资产负债 |
每股账面净值
1.99
|
现金流量 |
现金流量率
--
|
损益表 |
收益
8.56K
|
每股收益
0.00
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

同行比较之报价最少15分钟延迟
业务概览
|
|||
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developinga proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus. |